Duearity AB's subsidiary in the US, Duearity Americas Inc, has signed agreements with the first five clinics. The clinics intend to purchase Tinearity G1 for their tinnitus patients. A reasonable assessment is that approximately ten clinics in the US have entered into agreements with the company during the third quarter of 2023.

Duearity Americas Inc. has signed evaluation agreements with five clinics in the United States that intend to purchase Tinearity G1 for their tinnitus patients. The agreements mean that Duearity Americas Inc. can carry out the first sales during the third quarter. Duearity received market approval on June 30 this year and sales activities started immediately after that.

The assessment is that Duearity Americas Inc. has entered into agreements with approximately ten clinics before the end of the third quarter.